Clinical and Prognostic Significance of MiR-155 and MiR-146a Expression Levels in Formalin-fixed/paraffin-embedded Tissue of Patients with Diffuse Large B-cell Lymphoma

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2012 Sep 13

PMID 22969965

Citations 33

Authors

Hua Zhong

Lan Xu

Ji-Hua Zhong

Fei Xiao

Qiang Liu

Hong-Hui Huang

Fang-Yuan Chen

Affiliations

Soon will be listed here.

Abstract

It has been found that aberrant expression of microRNAs (miRNAs) is strongly associated with carcinogenesis. In the present study, we investigated the expression of miR-155 and miR-146a in diffuse large B-cell lymphoma (DLBCL) patients (n=90). The expression levels of miR-155 and miR-146a were significantly higher in de novo DLBCL patients. miR-146a expression levels were associated with miR-155, lactate dehydrogenase, β 2 microglobulin, c-myc, International Prognostic Index status and Eastern Cooperative Oncology Group performance status. We found that patients with low miR-155 and miR-146a expression levels achieved a higher complete remission rate, higher overall response rate and longer progression-free survival time. Moreover, a high expression level of miR-155, but not miR-146a, was an independent indicator for chemotherapy protocol selection in our study. Patients with high expression of miR-155 received more survival benefits from rituximab treatment. These data suggest that miR-155 and miR-146a have potential as diagnostic and prognostic markers in DLBCL.

Citing Articles

MicroRNA as a Potential Diagnostic and Prognostic Biomarker in Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis.

Khanmohammadi S, Masrour M, Fallahtafti P, Hasani F Cancer Rep (Hoboken). 2025; 8(1):e70070.

PMID: 39854617 PMC: 11760998. DOI: 10.1002/cnr2.70070.

The Role of microRNA-155 as a Biomarker in Diffuse Large B-Cell Lymphoma.

Koumpis E, Georgoulis V, Papathanasiou K, Papoudou-Bai A, Kanavaros P, Kolettas E Biomedicines. 2025; 12(12.

PMID: 39767565 PMC: 11673977. DOI: 10.3390/biomedicines12122658.

Prognostic impact of miR-125b and miR-155b and their relationship with MYC and TP53 in diffuse large B-cell lymphoma: cell-of-origin classification matters.

Neves Filho E, Zancheta S, Barros Silva P, Burbano R, Rabenhorst S J Clin Exp Hematop. 2023; 63(3):164-172.

PMID: 37766562 PMC: 10628825. DOI: 10.3960/jslrt.23009.

Potential Pathogenic Impact of Cow's Milk Consumption and Bovine Milk-Derived Exosomal MicroRNAs in Diffuse Large B-Cell Lymphoma.

Melnik B, Stadler R, Weiskirchen R, Leitzmann C, Schmitz G Int J Mol Sci. 2023; 24(7).

PMID: 37047075 PMC: 10094152. DOI: 10.3390/ijms24076102.

Effect of miR-27b on the proliferation and apoptosis of diffuse large b-cell lymphoma cells by targeting the regulation of MET/PI3K/AKT pathway.

Zhang R, Huang T, Li J, Zhou H, Wang X Discov Oncol. 2022; 13(1):137.

PMID: 36502446 PMC: 9742074. DOI: 10.1007/s12672-022-00589-9.

References

Lawrie C, Chi J, Taylor S, Tramonti D, Ballabio E, Palazzo S . Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med. 2009; 13(7):1248-60. PMC: 4496139. DOI: 10.1111/j.1582-4934.2008.00628.x. View

Eis P, Tam W, Sun L, Chadburn A, Li Z, Gomez M . Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A. 2005; 102(10):3627-32. PMC: 552785. DOI: 10.1073/pnas.0500613102. View

Alizadeh A, Eisen M, Davis R, Ma C, Lossos I, Rosenwald A . Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-11. DOI: 10.1038/35000501. View

Georgantas 3rd R, Hildreth R, Morisot S, Alder J, Liu C, Heimfeld S . CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci U S A. 2007; 104(8):2750-5. PMC: 1796783. DOI: 10.1073/pnas.0610983104. View

Kota S, Balasubramanian S . Cancer therapy via modulation of micro RNA levels: a promising future. Drug Discov Today. 2010; 15(17-18):733-40. DOI: 10.1016/j.drudis.2010.07.003. View

Braun T, Carvalho G, Fabre C, Grosjean J, Fenaux P, Kroemer G . Targeting NF-kappaB in hematologic malignancies. Cell Death Differ. 2006; 13(5):748-58. DOI: 10.1038/sj.cdd.4401874. View

Calin G, Ferracin M, Cimmino A, Di Leva G, Shimizu M, E Wojcik S . A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005; 353(17):1793-801. DOI: 10.1056/NEJMoa050995. View

Lenz G, Wright G, Emre N, Kohlhammer H, Dave S, Davis R . Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A. 2008; 105(36):13520-5. PMC: 2533222. DOI: 10.1073/pnas.0804295105. View

Lawrie C . MicroRNA expression in lymphoid malignancies: new hope for diagnosis and therapy?. J Cell Mol Med. 2008; 12(5A):1432-44. PMC: 3918059. DOI: 10.1111/j.1582-4934.2008.00399.x. View

10.

Kluiver J, Poppema S, de Jong D, Blokzijl T, Harms G, Jacobs S . BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol. 2005; 207(2):243-9. DOI: 10.1002/path.1825. View

11.

Lawrie C, Soneji S, Marafioti T, Cooper C, Palazzo S, Paterson J . MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer. 2007; 121(5):1156-61. DOI: 10.1002/ijc.22800. View

12.

Monticelli S, Ansel K, Xiao C, Socci N, Krichevsky A, Thai T . MicroRNA profiling of the murine hematopoietic system. Genome Biol. 2005; 6(8):R71. PMC: 1273638. DOI: 10.1186/gb-2005-6-8-r71. View

13.

Thompson R, Herscovitch M, Zhao I, Ford T, Gilmore T . NF-kappaB down-regulates expression of the B-lymphoma marker CD10 through a miR-155/PU.1 pathway. J Biol Chem. 2010; 286(3):1675-82. PMC: 3023462. DOI: 10.1074/jbc.M110.177063. View

14.

Thai T, Calado D, Casola S, Ansel K, Xiao C, Xue Y . Regulation of the germinal center response by microRNA-155. Science. 2007; 316(5824):604-8. DOI: 10.1126/science.1141229. View

15.

Calin G, Sevignani C, Dumitru C, Hyslop T, Noch E, Yendamuri S . Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004; 101(9):2999-3004. PMC: 365734. DOI: 10.1073/pnas.0307323101. View

16.

Visone R, Rassenti L, Veronese A, Taccioli C, Costinean S, Aguda B . Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood. 2009; 114(18):3872-9. PMC: 2773482. DOI: 10.1182/blood-2009-06-229211. View

17.

Zhang H, Luo X, Zhang P, Huang L, Zheng Y, Wu J . MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia. PLoS One. 2009; 4(11):e7826. PMC: 2773830. DOI: 10.1371/journal.pone.0007826. View

18.

Kim V . MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol. 2005; 6(5):376-85. DOI: 10.1038/nrm1644. View

19.

Volinia S, Calin G, Liu C, Ambs S, Cimmino A, Petrocca F . A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006; 103(7):2257-61. PMC: 1413718. DOI: 10.1073/pnas.0510565103. View

20.

Wang Y, Li Z, He C, Wang D, Yuan X, Chen J . MicroRNAs expression signatures are associated with lineage and survival in acute leukemias. Blood Cells Mol Dis. 2010; 44(3):191-7. PMC: 2829339. DOI: 10.1016/j.bcmd.2009.12.010. View